A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma

A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with newly Diagnosed Diffuse Large B-cell Lymphoma

Trial Details

NCT ID
NCT06683885
Phase
PHASE1 / PHASE2
Sponsor
Mingzhi Zhang
Status
RECRUITING
Cancer Type
Diffuse Large B-Cell (DLBCL) Lymphoma
Interventions
  • Obutinib or Decitabine, Rituximab, Compound Cyclophosphamide Tablets and Prednisone
Locations (sample)
  • Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

  • Individuals aged 65 years or older who are intolerant to chemotherapy, regardless of gender;
  • ECOG 0-1; IPI score ≤ 3 points;
  • Expected survival period of more than 3 months;
  • DLBCL diagnosed by tissue biopsy pathology;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Diffuse Large B-Cell (DLBCL) Lymphoma Trials on Trialify →